Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is 309.66% higher on its value in year-to-date trading and has touched a low of $1.05 and a high of $7.41 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRVS stock was last observed hovering at around $7.35 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $7.21, the stock is 24.08% and 46.21% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.84 million and changing -1.90% at the moment leaves the stock 161.34% off its SMA200. CRVS registered 422.46% gain for a year compared to 6-month gain of 411.35%. The firm has a 50-day simple moving average (SMA 50) of $4.9312 and a 200-day simple moving average (SMA200) of $2.758825.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 31.57% loss in the last 1 month and extending the period to 3 months gives it a 230.73%, and is 24.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.13% over the week and 8.17% over the month.
Corvus Pharmaceuticals Inc (CRVS) has around 28 employees, a market worth around $450.99M and $0.00M in sales. Distance from 52-week low is 586.67% and -2.70% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.15%).
Corvus Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -0.1.The EPS is expected to grow by 26.34% this year
54.0 institutions hold shares in Corvus Pharmaceuticals Inc (CRVS), with institutional investors hold 46.04% of the company’s shares. The shares outstanding are 62.55M, and float is at 50.12M with Short Float at 4.29%. Institutions hold 44.19% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 6.94 million shares valued at $12.64 million. The investor’s holdings represent 14.1596 of the CRVS Shares outstanding. As of 2024-06-30, the second largest holder is SAMLYN CAPITAL, LLC with 6.12 million shares valued at $11.14 million to account for 12.4861 of the shares outstanding. The other top investors are POINT72 ASSET MANAGEMENT, L.P. which holds 5.96 million shares representing 12.1629 and valued at over $10.86 million, while ADAMS STREET PARTNERS LLC holds 6.6797 of the shares totaling 3.28 million with a market value of $5.96 million.
Corvus Pharmaceuticals Inc (CRVS) Insider Activity
The most recent transaction is an insider purchase by Jones William Benton, the company’s. SEC filings show that Jones William Benton bought 20,000 shares of the company’s common stock on May 06 ’24 at a price of $1.73 per share for a total of $34624.0. Following the purchase, the insider now owns 0.15 million shares.
Corvus Pharmaceuticals Inc disclosed in a document filed with the SEC on May 06 ’24 that MILLER RICHARD A MD (President and CEO) bought a total of 577,634 shares of the company’s common stock. The trade occurred on May 06 ’24 and was made at $1.73 per share for $1.0 million. Following the transaction, the insider now directly holds 0.58 million shares of the CRVS stock.
